share_log

Clearmind Medicine | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Clearmind Medicine | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Clearmind Medicine | 6-K:外国发行人报告
美股sec公告 ·  05/07 16:06
Moomoo AI 已提取核心信息
Clearmind Medicine Inc., a clinical-stage biotech company, has announced the signing of an exclusive patent licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. This agreement, announced on May 7, 2024, grants Clearmind exclusive global rights to develop, manufacture, and commercialize novel psychedelic compounds for the treatment of PTSD and other mental health conditions. The compounds, invented by Professors Rami Yaka, Ahmed Masaewa, and Avi Priel, are seen as a significant advancement in the treatment of PTSD, a market projected to grow to $27.37 billion by 2033. Clearmind's CEO, Dr. Adi Zullof-Shani, expressed optimism about the potential of these compounds to address urgent mental health care needs. The agreement includes milestone payments, royalties on future sales, and commitments to protect intellectual property rights. Clearmind, listed on Nasdaq and the Frankfurt Stock Exchange, is focused on developing psychedelic-derived therapeutics for underserved health problems, including alcohol use disorder.
Clearmind Medicine Inc., a clinical-stage biotech company, has announced the signing of an exclusive patent licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. This agreement, announced on May 7, 2024, grants Clearmind exclusive global rights to develop, manufacture, and commercialize novel psychedelic compounds for the treatment of PTSD and other mental health conditions. The compounds, invented by Professors Rami Yaka, Ahmed Masaewa, and Avi Priel, are seen as a significant advancement in the treatment of PTSD, a market projected to grow to $27.37 billion by 2033. Clearmind's CEO, Dr. Adi Zullof-Shani, expressed optimism about the potential of these compounds to address urgent mental health care needs. The agreement includes milestone payments, royalties on future sales, and commitments to protect intellectual property rights. Clearmind, listed on Nasdaq and the Frankfurt Stock Exchange, is focused on developing psychedelic-derived therapeutics for underserved health problems, including alcohol use disorder.
临床阶段的生物技术公司Clearmind Medicine Inc. 宣布与耶路撒冷希伯来大学的Yissum研究开发公司签署独家专利许可协议。该协议于2024年5月7日宣布,授予Clearmind开发、制造和商业化用于治疗创伤后应激障碍和其他心理健康状况的新型迷幻化合物的全球独家权利。这些化合物由拉米·亚卡教授、艾哈迈德·马萨瓦教授和阿维·普里尔教授发明,被视为创伤后应激障碍治疗领域的重大进展,预计到2033年,创伤后应激障碍的市场将增长到273.7亿美元。Clearmind的首席执行官阿迪·祖洛夫-沙尼博士对这些化合物解决紧急心理保健需求的潜力表示乐观。该协议包括里程碑付款、未来销售的特许权使用费和保护知识产权的承诺。Clearmind在纳斯达克和法兰克福证券交易所上市,专注于开发迷幻药衍生疗法,以解决服务不足的健康问题,包括酒精使用障碍。
临床阶段的生物技术公司Clearmind Medicine Inc. 宣布与耶路撒冷希伯来大学的Yissum研究开发公司签署独家专利许可协议。该协议于2024年5月7日宣布,授予Clearmind开发、制造和商业化用于治疗创伤后应激障碍和其他心理健康状况的新型迷幻化合物的全球独家权利。这些化合物由拉米·亚卡教授、艾哈迈德·马萨瓦教授和阿维·普里尔教授发明,被视为创伤后应激障碍治疗领域的重大进展,预计到2033年,创伤后应激障碍的市场将增长到273.7亿美元。Clearmind的首席执行官阿迪·祖洛夫-沙尼博士对这些化合物解决紧急心理保健需求的潜力表示乐观。该协议包括里程碑付款、未来销售的特许权使用费和保护知识产权的承诺。Clearmind在纳斯达克和法兰克福证券交易所上市,专注于开发迷幻药衍生疗法,以解决服务不足的健康问题,包括酒精使用障碍。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息